C167 (Lamivudine 300 mg)
Pill with imprint C167 is White, Capsule-shape and has been identified as Lamivudine 300 mg. It is supplied by Cipla USA Inc.
Lamivudine is used in the treatment of hiv infection; hepatitis b; nonoccupational exposure; occupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). Risk cannot be ruled out during pregnancy. Lamivudine 300 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for C167
Lamivudine
- Imprint
- C167
- Strength
- 300 mg
- Color
- White
- Size
- 17.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Cipla USA Inc.
- National Drug Code (NDC)
- 69097-0167
- Inactive Ingredients
-
hypromellose 2910 (15 mPa.s),
magnesium stearate,
microcrystalline cellulose,
sodium starch glycolate type B potato,
polyethylene glycol 6000,
corn starch,
titanium dioxide
Note: Inactive ingredients may vary.
More about lamivudine
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (5)
- Drug images
- Pricing & coupons
- En español
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
Patient resources
- Other brands
- Epivir, Epivir-HBV
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.